Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 1246 AL 1260

Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease

Toda Y, Iwatsubo T, Nakamura Y, Matsuda N, Miyata M, Jin M, Chen T, Kuribayashi K, Tian Y, Hughes R, Yamamoto J, Muralidharan KK, Rubel C, Hutchison RM, Budd Haeberlein S.

J Prev Alzheimers Dis. 2024;11(5):1260-1269. doi: 10.14283/jpad.2024.106.

Alzheimer's disease biomarkers and the tyranny of treatment

Karlawish J, Grill JD.

EBioMedicine. 2024 Oct;108:105291. doi: 10.1016/j.ebiom.2024.105291. Epub 2024 Oct 3.

Insights into the use of biomarkers in clinical trials in Alzheimer's disease

Pascoal TA, Aguzzoli CS, Lussier FZ, Crivelli L, Suemoto CK, Fortea J, Rosa-Neto P, Zimmer ER, Ferreira PCL, Bellaver B.

EBioMedicine. 2024 Oct;108:105322. doi: 10.1016/j.ebiom.2024.105322. Epub 2024 Oct 3.

Survival time in Alzheimer's disease: An overlooked measure of safety and efficacy of disease-modifying therapies

Kurkinen M, Daly T.

Adv Clin Exp Med. 2024 Oct;33(10):1039-1043. doi: 10.17219/acem/194003.

A meta-analysis of bulk RNA-seq datasets identifies potential biomarkers and repurposable therapeutics against Alzheimer's disease

Lamisa AB, Ahammad I, Bhattacharjee A, Hossain MU, Ishtiaque A, Chowdhury ZM, Das KC, Salimullah M, Keya CA.

Sci Rep. 2024 Oct 21;14(1):24717. doi: 10.1038/s41598-024-75431-z.

Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology

Schauer SP, Toth B, Lee J, Honigberg LA, Ramakrishnan V, Jiang J, Kollmorgen G, Bayfield A, Wild N, Hoffman J, Ceniceros R, Dolton M, Bohórquez SMS, Hoogenraad CC, Wildsmith KR, Teng E, Monteiro C, Anania V, Yeh FL.

Alzheimers Dement. 2024 Dec;20(12):8855-8866. doi: 10.1002/alz.14346. Epub 2024 Nov 8.

Public-Private Partnerships for Neuropsychiatric Drug Development: A Perspective

Potter WZ.

Adv Neurobiol. 2024;40:67-85. doi: 10.1007/978-3-031-69491-2_3.

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217

Kovacech B, Cullen NC, Novak P, Hanes J, Kontsekova E, Katina S, Parrak V, Fresser M, Vanbrabant J, Feldman HH, Winblad B, Stoops E, Vanmechelen E, Zilka N.

Alzheimers Res Ther. 2024 Nov 23;16(1):254. doi: 10.1186/s13195-024-01620-7.

Medication Exposure and Risk of Dementia and Alzheimer's Disease

Sharma N, An SSA, Kim SY.

Int J Mol Sci. 2024 Nov 29;25(23):12850. doi: 10.3390/ijms252312850.

Understanding the Molecular Impact of Physical Exercise on Alzheimer's Disease

Cantón-Suárez A, Sánchez-Valdeón L, Bello-Corral L, Cuevas MJ, Estébanez B.

Int J Mol Sci. 2024 Dec 18;25(24):13576. doi: 10.3390/ijms252413576.

The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease

Bland AR, Ashton JC, Kamal MA, Sahebkar A.

CNS Neurol Disord Drug Targets. 2023;22(3):318-320. doi: 10.2174/1871527321666220119105836.

Impact of the Cannabinoid System in Alzheimer's Disease

Li S, Huang Y, Yu L, Ji X, Wu J.

Curr Neuropharmacol. 2023;21(3):715-726. doi: 10.2174/1570159X20666220201091006.

Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer's Disease

Barbosa FAR, Canto RFS, Teixeira KF, de Souza AS, de Oliveira AS, Braga AL.

Curr Med Chem. 2023;30(6):689-700. doi: 10.2174/0929867329666220224161454.

Epigenetic Modifications by Estrogen and Androgen in Alzheimer's Disease

Kumar R, Fatima F, Yadav G, Singh S, Haldar S, Alexiou A, Ashraf GM.

CNS Neurol Disord Drug Targets. 2023;22(1):6-17. doi: 10.2174/1871527321666220225110501.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias